MARROW TRANSPLANTATION FOR THALASSAEMIA
E. Donnall Thomas(AbbVie (United States)), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jean E. Sanders(Carolinas Medical Center), Caterina Borgna‐Pignatti(University of Washington), ReginaldA Clift(University of Washington), CD Buckner(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Piero De Stefano(University of Washington), K M Sullivan(Fred Hutch Cancer Center), Thalia Papayannopoulou(Seattle Pacific University)
Cited by 335
Related Papers
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k